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Objective: To describe omalizumab (Xolairs) effectiveness in the first patients treated on
compassionate grounds before its commercialisation in France.
Methods: In a historic-prospective study, data were obtained by questionnaire from the
physicians whose patients had received a nominative temporary use authorisation (ATU)
for omalizumab from July 2003 to January 2006. Anonymised patient data regarding
demographics, asthma-related treatments and events in the year previous to the start of
omalizumab treatment as well as the details of omalizumab treatment itself were
obtained at inclusion. Follow-up data at more than 3 months following inclusion were also
obtained and regarded asthma-related treatment (including omalizumab), events and
undesirable effects suspected to be linked to omalizumab treatment.
Results: Data were obtained for 147 of the 154 patients treated via ATU. 31.3% received
inappropriate monthly doses of omalizumab. Of the 28 patients (19%) who discontinued for
unsatisfactory therapeutic effect, 7 were treated for less than the 16 weeks recommended
to evaluate efficacy and 9 who were treated for a longer period of time were underdosed.
During the treatment period and compared to the previous year, patients with follow-up
data at 5 months or more had experienced 62% fewer exacerbations requiring oral
corticosteroids, 65% fewer emergency department visits and 29% fewer hospitalisations per
year. The nature of adverse effects reported was similar to that reported in omalizumab
clinical trials.
Conclusion: Results strongly suggest that omalizumab in the first patients treated in real-
life setting provided a similar benefit to that observed in clinical trials. Underdosing of
patients may limit this therapeutic effect.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
571560; fax: +33 557574671.
pharmaco.u-bordeaux2.fr (M. Molimard).
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M. Molimard et al.72Introduction demographics (date of birth, sex), asthma-related treat-Therapeutic approaches to asthma are determined by both
severity of clinical features and disease control; the Global
Initiative For Asthma (GINA) describe four levels of severity
and three levels of control.1 Patients with inadequately
controlled asthma are more at risk of associated morbidity
and mortality, with which comes a greater use of medical
resources and thus a greater cost.2 Following guidelines,
control can be achieved for most patients however there
still exists a refractory population for whom asthma remains
inadequately controlled. For patients who suffer from
severe persistent asthma inadequately controlled by high
doses of inhaled corticosteroids and long-acting b2-agonists,
asthma is deemed hard-to-treat.1,3 The humanised anti-IgE
antibody omalizumab (Xolairs) has recently been intro-
duced to the market and included in a step 5 therapy
alongside oral corticosteroids.1 In clinical trials, it has
demonstrated its efficacy in patients suffering from allergic
asthma, improving control by reducing exacerbations,
hospital use as well as that of corticosteroids.4–11 In a
retrospective pooled analysis of two phase III placebo-
controlled clinical trials, it was found that factors associated
with more severe asthma were indicators of favourable
response to omalizumab.12 A suggestion further supported
by the INNOVATE study8 which investigated omalizumab in
patients with inadequately controlled severe persistent
allergic asthma despite GINA step 4 therapy (difficult-to-
treat asthma). The results of this study were pivotal for the
European market authorisation granted in October 2005 and
data regarding omalizumab use in real-life or effectiveness
have yet to be published.
Omalizumab was made available in France on compassio-
nate grounds before market authorisation and commercia-
lisation via nominative temporary use authorisations
(utilisation temporaire d’utilisation, ATU). These are
granted by the French authority: Agence Franc-aise de
Securite´ Sanitaire des Produits de Sante´ (AFSSaPS) for drugs
that reply to certain criteria including the treatment of
serious or rare diseases for which no authorised treatment is
available. In contrast to clinical trials, this system is not
designed to prove the efficiency of the drug. Nominative
ATUs are delivered to individual patients on a case-by-case
basis following application by a hospital physician.13
Nominative ATUs were issued by the AFSSaPS from July
2003 until 13 January 2006 after the market authorisation of
omalizumab. The present study describes the characteristics
of patients and the effectiveness of omalizumab in the first
large group of patients who received this treatment during
the ATU setting.Methods
This was a historic-prospective study performed on patients
having obtained a nominative ATU for omalizumab during
the period: July 2003–January 2006.
The physicians of all patients having obtained a nomina-
tive ATU were identified by the issuing body (AFSSaPS)
and sent a two-part questionnaire by Novartis Pharma.
The first part of the questionnaire concerned the period
before omalizumab treatment (initial data) and regarded:ments (inhaled corticosteroids, long-acting b2-agonists, oral
corticosteroids), number of asthma-related events during
the 12 months previous to the start of omalizumab
treatment (exacerbations requiring oral corticosteroids,
emergency visits, hospitalisations) and omalizumab treat-
ment (weight of patient, total IgE, dose and frequency of
omalizumab administration, date of first administration).
The second part of the questionnaire concerned follow-up to
be completed at more than 3 months after the start of
omalizumab treatment. This section regarded: treatment
interruption (date of last administration, reason), date of
last clinical evaluation whilst still under treatment, mod-
ification of asthma-related treatments (inhaled corticoster-
oids, long-acting b2-agonists, oral corticosteroids), the
number of asthma-related events since the start of
omalizumab treatment (exacerbations requiring oral corti-
costeroids, emergency visits, hospitalisations) and undesir-
able effects suspected to be linked to omalizumab
treatment (as defined in France by decree no. 2004-99).
To obtain longer term data, a second questionnaire was sent
in January 2006 for patients still treated with omalizumab,
who received a nominative ATU up to September 2005
(inclusive) and whose physicians sent back the first ques-
tionnaire. Data collection ended at the end of April 2006.
All physicians, pharmacists and midwives observing a
serious undesirable effect suspected to be linked to
omalizumab were to immediately notify (less than 24 h)
Novartis Pharma using the form provided. Any other member
of the medical profession was also able to notify Novartis
Pharma of such an observation. Any pregnancy occurring
during the treatment period was to be reported using the
form provided.
Due to its mechanism of action, the European Medicines
Agency (EMEA) recommends that omalizumab treatment
effectiveness be assessed after 16 weeks of treatment.14 In
the study population, effectiveness over the treatment
period (annual rate of events and corticosteroid use) was
evaluated in patients with follow-up data at more than 5
months. Analyses were descriptive and annual rates calcu-
lated using patient-years. All patients treated at least once
were considered for safety evaluation.Results
Population
During the period July 2003–January 2006, 160 nominative
ATUs for omalizumab were delivered and 154 patients really
treated. Questionnaires were returned for 147 patients, 146
of which were prescribed omalizumab for severe persistent
uncontrolled allergic asthma and one for hymenoptera
venom allergy (Table 1).
Using available data for patients treated by omalizumab
with asthma indication, all were inhaled corticosteroids and
long-acting b2-agonists users at inclusion, and 54 were users
of continuous oral corticosteroids (Table 2). In the year
previous to treatment, all patients had experienced
frequent exacerbations (mean ¼ 5.5), emergency visits
(mean ¼ 3) and hospitalisation (mean ¼ 1.5). For patients
with follow-up data at 5 months or longer, the annual rate of
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Table 1 Study population.
Patients with data
(n ¼ 147)
Indication 147
Uncontrolled severe persistent
allergic asthma, n
146
Hymenoptera venom allergy, n 1
Sex (female), mean (%) 63.3
Age (years), mean7SD 46.5713.55
Weight (kg), mean7SD 71.3715.95
Total IgE (IU/mL), mean7SD 283.47228.74
Table 2 Anti-asthmatic treatments at inclusion.
Patients with
uncontrolled
severe allergic
asthma (n ¼ 146)
Inhaled corticosteroid use
Patients with data, n 146
Users, n (%) 146 (100)
Dose (mg BDP equivalent/day), mean7SD 3071.271579.52
Continuous oral corticosteroids
Patients with data, n 87
Users, n (%) 54 (62)
Dose (mg/day), mean7SD 26.5720.49
Long-acting inhaled b2-agonists
Patients with data, n 145
Users, n (%) 145 (100)
Formoterol
n (%) 70 (48.3)
Dose (mg/day), mean7SD 45.4721.22
Salmeterol
n (%) 75 (51.7)
Dose (mg/day), mean7SD 182.7773.40
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Figure 1 Rate of asthma-related events for patients with follow-up
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Pre-approval omalizumab treatment in France 73exacerbations decreased by 62%, emergency visits by 65%
and hospitalisations by 29% (Figure 1). During treatment, the
proportion of patients not having an exacerbation event rose
by 241%, those not having an emergency visit by 69% and
those not being hospitalised by 53% (Figure 2). These
patients also lowered their use of corticosteroids: 25.6%
reduced or discontinued inhaled corticosteroid use and
48.1% reduced or discontinued continuous oral corticoster-
oid use (Figure 3).
Omalizumab treatment
The mean monthly dose of omalizumab was 404mg and
was administered every 4 weeks in 51% of the patients
and the mean number of vials used monthly was 3. With
respect to the dosage instructions, 31.3% (n ¼ 46) of the
patients received inappropriate monthly doses of omalizu-
mab (13 overdosed and 33 underdosed), 56.5% of these (17%
of the total population) had weight and total IgE within the
dosage table range. Nearly one-third of the patients
discontinued treatment (n ¼ 45, 30.6%). The physicians
most often cited unsatisfactory therapeutic effect as the
reason for discontinuation (n ¼ 28, 19%). Of these, 21 were
treated for more than 16 weeks (9 were underdosed) and 7
were treated for less than 16 weeks (3 were underdosed)
(Table 3). Discontinuation for unsatisfactory therapeutic
effect was found in 15.0% of those who received correct
dosage (n ¼ 101), whereas this was 7.7% in overdosed
patients (n ¼ 13) and in 36.4% of underdosed patients
(n ¼ 33).
Adverse effects
Over all, 26.5% (n ¼ 39) of the patients having received
omalizumab experienced at least one adverse effect, five of
which experienced severe effects. The most frequently
reported adverse effects were headache (n ¼ 12), asthenia
(n ¼ 6), local reaction at point of injection (n ¼ 5) and
nausea (n ¼ 5) (Table 4). Severe adverse effects werency visits Hospitalizations
1.1 
1.7 
1.2 
-29% 
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%
data at more than 5 months. The annual rate of exacerbations
ospitalisations per patient-year is shown in black for the year
od. The number of patients with data is indicated (n).
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M. Molimard et al.74asthenia, irritability, headache, hypersensitivity convul-
sions, myalgia, arthralgia and periarthritis. Only two
patients experiencing a severe adverse effect discontinued
treatment.Discussion
This study is the description of the first large group of
patients treated in France by omalizumab outside clinical
trials. The patients studied here were exclusively prescribed
omalizumab via nominative ATUs. The issuing body, AFSSaPS,
based their judgment for asthmatic patients on the results
of the INNOVATE study which was performed on step 4
severe persistent asthma patients following the GINA 20020
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Users of inhaled or oral corticosteroids who increased dose (blac
discontinued use (white) is shown as well as the number of patientasthma severity classification.8 The majority of ATUs were
delivered to very severe uncontrolled asthmatic patients.
This is reflected in the study population by the mean daily
dose of inhaled corticosteroids and the rate of asthma-
related events in the year preceding omalizumab treatment.
The high rate of exacerbations indicate that asthma in these
patients was uncontrolled by their already high use of
medication and the rate of emergency visits and hospitalisa-
tions highlights the severity of these.15 Comparison of base-
line characteristics indicate that the population described
here experienced a higher rate of asthma-related events
than that investigated in the INNOVATE study. Almost 30% of
the population used more than 20mg oral maintenance
corticosteroids, an exclusion criterion for the INNOVATE
study. Yet we report that 28 patients or 19% of the studyency visits Hospitalizations
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Table 3 Omalizumab treatment.
Total population
(n ¼ 147)
Overdosed
(n ¼ 13)
Underdosed
(n ¼ 33)
Continued treatment, n (%) 101 (68.7) 11 15
Discontinuation of treatment, n (%) 45 (30.6) 2 18
Reason for discontinuation
Unsatisfactory therapeutic effect 28 (19.0) 1 12
At 416 weeks of treatment 21 (14.3) 1 9
Adverse effect 8 (5.4) 1 2
No longer clinically required 2 (1.4) 0 3
Patient’s wish 2 (1.4) 0 0
Death 1 (0.7) 0 0
Other 4 (2.7) 0 1
Not suspected to be related to treatment.
Table 4 Undesirable effects.
Total population
(n ¼ 147), n (%)
Patients with X1 adverse effect 39 (26.5)
Which led to treatment discontinuation 8 (5.4)
With severe adverse effect 5 (3.4)
Most frequent adverse effects
Headache 12 (8.2)
Asthenia 6 (4.1)
Local reaction (at point of injection) 5 (3.4)
Nausea 5 (3.4)
Vomiting 4 (2.7)
Fatigue 4 (2.7)
Arthralgia 3 (2.0)
Myalgia 3 (2.0)
Vertigo 3 (2.0)
Thoracic pain 3 (2.0)
Flu-type symptoms 2 (1.4)
Unease 2 (1.4)
Irritability 2 (1.4)
Weight gain 2 (1.4)
Dyspnea 2 (1.4)
Prurit 2 (1.4)
Pre-approval omalizumab treatment in France 75population discontinued for unsatisfactory therapeutic
response. Interestingly, twice more underdosed patients
than correctly dosed patients were found to discontinue for
this reason and when the recommended minimal duration of
treatment is taken into account, 16 were undertreated
(10.8% of the total population). Four were treated for less
than the recommended 16 weeks to perform treatment
evaluation, 9 were underdosed and 3 both treated for less
than 16 weeks and underdosed. Such undertreatment may
be explained by the nature of the present study, more close
to a post-marketing investigation that gives more flexibility
to the prescriber. Not all patients who were treated fell
within the range of the dosing table that considers total IgE
concentration and weight. These patients accounted forapproximately half of the inappropriately dosed patients
(for review of dosing, see Lanier and Marshall16). More
surprisingly, however, was the finding that nearly 17% of the
treated population who were within the dosing table were
inappropriately dosed, 9% being underdosed. This is of
particular note interesting in the light of the results
discussed above regarding discontinuation for unsatisfactory
therapeutic response and correct dosing should be stressed
in future recommendations for use. Although the causal
relationship between undertreatment and unsatisfactory
therapeutic effect could have been strengthened by a more
formal assessment of disease control at inclusion and follow-
up, such intervention could have modified prescriber
behaviour and detract from the real-life nature of the
study. This does not, however, diminish the principal
observation relating to undertreatment.
Results of effectiveness presented here strongly suggest
that the efficacy demonstrated in RCTs4–11 can be trans-
posed to a real-life setting. The magnitude of the improve-
ment compared to the previous year was comparable to that
observed in RCTs. These results are tempered by several
limitations that reflect the real-life nature of this study.
Indeed, compared to RCTs, this study required retrospective
comparison: previous studies based their measurements on a
comparison with a control group, either placebo6–8,10,11 or
non-treated4 whereas here, effectiveness during treatment
was compared to the previous year. Furthermore, confound-
ing factors such as the placebo effect or a more strict
compliance for existing medications due to more frequent
physician contact17 could not be taken into account.
However, aside from the requirement to obtain a nominative
ATU, prescribing practices were similar to those found
after commercialisation and thus reflect real-life conditions
of use.
Omalizumab was overall well tolerated although adverse
effects were present in over a quarter of the patients
treated. The most frequent adverse effects described have
already been described in the literature: headache,4,8,9,11
asthenia (fatigue),10 local injection site reaction6–8,10,11 and
nausea.9 The majority were relatively mild as only eight
patients discontinued for reason of an adverse effect and
five experienced a severe adverse effect.
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M. Molimard et al.76In conclusion, this first study of omalizumab use in real-
life practice strongly suggests that it delivers a clinically
relevant benefit in a population of very poorly controlled
severe asthmatic patients. A number of patients were
undertreated and this may limit therapeutic effect.
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